Strangely enough, I know someone (a very close relationship, not the typical third-derivative friend of an uncle so popular in bizarre cases like this) that honestly prefers a dose of (2R,3S)-(-)-ephedrine (at 50 - 75mg over two hours or so) to a psychoactive dose of enantiopure (d)-amphetamine SR. This is not a one-time effect either--said person has been offered (d)-amphetamine several times with full pharmacological "briefing" on the comparative catecholaminergic selectivity (NA/DA ED50 ratio) of the two compounds and selected (-)-ephedrine. Also, this person's favourite chemical experience was (2S,3S)-phendimetrazine, a chemical noted for its lack of so-called "recreational" effects compared to (d)-amphetamine and the impossibly elusive (2S,3S)-phenmetrazine.
Some people seem to enjoy noradrenaline release; sometimes times truth is stranger than fiction. As for (2S,3S)-(+)-ephedrine (pseudoephedrine), I don't think that it has as much of a central effect as (-)-ephedrine, so (-)-ephedrine should be more "enjoyable." There is a little bit of empirical evidence for this, mainly from Rothman et al: "The most potent actions of ephedrine-type compounds were as substrates of the norepinephrine transporter (EC50 values of about 50 nM) followed by substrate activity at the dopamine transporter. Screening the receptorome demonstrated weak affinity at alpha2-adrenergic and 5-hydroxytryptamine7 receptors (Ki values 1-10 microM) and no significant activity at beta-adrenergic or alpha1-adrenergic receptors. Viewed collectively, these data indicate that the pharmacological effects of ephedrine-like phenylpropanolamines are likely mediated by norepinephrine release, and although sharing mechanistic similarities with, they differ in important respects from those of the phenylpropanonamines methcathinone and cathinone and the phenyisopropylamines methamphetamine and amphetamine." (Rothman et al, 2003). In another study, Bondareva et al (2002) demonstrated that (-)-ephedrine possessed equipotent stimulus discrimination effects as those of (R)-methamphetamine, a drug known for its noradrenergic effects. Anderson et al (2001) showed that (-)-ephedrine fully substituted for (d)-amphetamine, but only when administered parenterally.
In my opinion, the jury is still out. Perhaps intersubject variation in DAT sequence (single nucleotide point mutations?) affects (-)-ephedrine sensitivity and "liking."